OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(7)
Transcriptomics
(1)
Organisms
Homo sapiens
(1)
Repository
biostudies-arrayexpress
(1)
Publication Date
2014
(1)
Study type
Other
(1)
Release Date
2014
(4)
2021
(2)
2024
(1)
2022
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
An atlas of active enhancers across human cell types and tissues
Sequencing of 5' ends of RNA molecules from control and exosome-depleted HeLa-S3 cells. CAGE library construction from RNA extracted from control and exosome-depleted cells.
ORGANISM(S):
Homo sapiens
2014-03-26
|
E-GEOD-49834
|
biostudies-arrayexpress
Cite
An atlas of active enhancers across human cell types and tissues.
Not available
S-EPMC5215096
|
biostudies-literature
Cite
Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation.
Not available
S-EPMC3986152
|
biostudies-literature
Cite
A promoter-level mammalian expression atlas.
Not available
S-EPMC4529748
|
biostudies-literature
Cite
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
Not available
S-EPMC12056793
|
biostudies-literature
Cite
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808
|
biostudies-literature
Cite
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995
|
biostudies-literature
Cite
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets